Genentech's 4Q Earnings Meet Expectations
11th Jan 2006, 16:42 GMT
Genentech 's robust earnings growth continued during 2005's final quarter amid strong demand for its cancer-fighting drugs, but the performance merely matched analyst expectations a letdown for investors who have become accustomed to bigger things from the biotech bellwether.
Genentech's 4Q Earnings Meet Expectations related news:
- Genentech's 4Q Earnings Match Expectations (AP) — Yahoo! News: Earnings News
- Genentech Shares Sink After 4Q Report (AP) — Yahoo! News: Earnings News
- Genentech's 4Q Earnings Match Expectations — Lancaster Online - Business
- Genentech Shares Sink After 4Q Report — washingtonpost.com -
- Genentech's Q4 earnings match analyst expectations — News -- SiliconValley.com
- Investors bail on Genentech after 4th-qtr earnings (Reuters) — Yahoo! News: Earnings News
- Genentech's fourth-quarter earnings match analyst expectations — SacBee -- Business
- Genentech matches, falls — The Globe and Mail - Business News
- Investors bail on Genentech after 4th-qtr earnings — washingtonpost.com -
- Stocks decline on Dupont profit warning — Breaking Business (AP)
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress